Clinical trials: Concurrent Chemoradiotherapy
Cervical Cancer Stage IVA, Cervical Cancer Metastatic
a Single Arm, Phase II Multicenter Clinical Trial to Evaluate the Efficacy and Safety of the Combination Therapy of Iparomlimab and Tuvonralima b and Chemotherapy ± Bevacizumab Induction Therapy Followed by Concurrent Chemoradiotherapy in Patients With Advanced Cervical Cancer .
This study is a single arm, phase II multicenter clinical trial to evaluate the efficacy and safety of the combination therapy of Iparomlimab and Tuvonralimab(QL1706) and chemotherapy ± bevacizumab induction therapy followed by…
- Trial name
- NCT07035808
- Testing
- 2 cycles of combined drug induction therapy: every 3 weeks for 2 cycles; After ,synchronous radiotherapy and chemotherapy combined immunotherapy
- Volunteers
- 46 people
- Sponsor
- Zhejiang Cancer Hospital
Limited Stage Small Cell Lung Cancer, Small Cell Lung Cancer
Study Evaluating Tarlatamab After Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer (LS-SCLC)
The primary objective of this study is to compare the efficacy of tarlatamab with placebo as assessed by progression free survival (PFS) based on blinded independent central review (BCIR) per response evaluation criteria in solid…
- Trial name
- DeLLphi-306 (NCT06117774)
- Testing
- Tarlatamab
- Where
- 204 sites in United States, Argentina and 25 more
- Volunteers
- 404 people
- Sponsor
- Amgen
Head and Neck Cancer, Oral Cancer
Circulating Tumor Cell Counts in Postoperative ENE-Positive Oral Cavity Cancer Patients After Adjuvant CCRT
The aim 1 of this trial is the development of the Circulating tumor cells (CTCs) definition of oral cancer minimal residual disease (MRD), and aim 2 is a prospective trial of oral cancer treatment.
- Trial name
- NCT07296250
- Testing
- low-dose oral chemotherapy
- Where
- Taiwan
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Chang Gung Memorial Hospital
Rectal Cancer
Consolidation Chemotherapy for Locally Advanced Mid or Low Rectal Cancer After Neoadjuvant Concurrent Chemoradiotherapy
This trial is to assess the efficacy and feasibility of consolidation chemotherapy after neoadjuvant chemoradiotherapy for locally advanced mid or low rectal cancer.
- Trial name
- NCT02843191
- Testing
- Chemotherapy
- Where
- 14 sites in South Korea
- Volunteers
- 358 people
- Sponsor
- Kyung Hee University Hospital at Gangdong
Colorectal Neoplasms Malignant, Lymph Node Excision
Chemoradiotherapy Sequenced Radical Surgery for Colorectal Cancer With PALNM
In left-sided colon and rectal cancer, the occurrence of synchronous para-aortic lymph node metastasis is rare, with the incidence of being approximate 1-2%.
- Conditions
- Colorectal Neoplasms Malignant, Lymph Node Excision, Chemoradiotherapy
- Trial name
- NCT05129774
- Testing
- Radical surgery with PALND, Radical surgery without PALND
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Qilu Hospital of Shandong University
Locally Advanced Lung Carcinoma
Fraction Dose Escalation of Hypo-fractionated Radiotherapy in LANSCLC
This Phase 1 trial aimed to determine the maximum tolerated fraction dose (MTD) of hypofractionated radiotherapy (hypo-RT) combined with concurrent chemotherapy and subsequent consolidation immune checkpoint inhibitors (cICI) for…
- Trial name
- NCT04951063
- Testing
- Hypofractionated radiotherapy, Concurrent chemotherapy, Consolidation immunotherapy
- Where
- China
- Volunteers
- 18 people
- Sponsor
- Sun Yat-sen University
Esophageal Squamous Cell Carcinoma
A Phase II Study of SHR-1210 vs Placebo as Consolidation Chemotherapy After Radical Concurrent Chemoradiotherapy in Locally Advanced ESCC
The purpose of this study is to observe and evaluate the efficacy and safety of SHR-1210 vs placebo as consolidation chemotherapy after radical concurrent chemoradiotherapy for unresectable locally advanced ESCC.
- Trial name
- NCT03817658
- Testing
- SHR-1210
- Where
- China
- Volunteers
- 725 people
- Sponsor
- The First Affiliated Hospital of Zhengzhou University
Gastroesophageal Junction Adenocarcinoma
Apatinib Plus Concurrent Neoadjuvant Chemoradiotherapy for Gastroesophageal Junction
The purpose of this study is to assess the efficacy and safety of patients who receive concurrent neoadjuvant chemoradiotherapy for Siewert II ，III of locally advanced HER-2 negative adenocarcinoma at gastroesophageal junction.
- Trial name
- NCT03986385
- Testing
- Apatinib Capecitabine Oxaliplatin, Capecitabine Oxaliplatin
- Where
- China
- Volunteers
- 180 people
- Sponsor
- Hebei Medical University
Nasopharyngeal Carcinoma
Induction Chemotherapy With GP Versus TPF in the Treatment of Advanced Nasopharyngeal Carcinoma
The present study is a randomized, control, phase II study of locally advanced nasopharyngeal carcinoma (NPC) treated with Gemcitabine plus cisplatin regimen (GP) or Docetaxel，cisplatin regimen plus 5-Fluorouracil (TPF) induction…
- Trial name
- NCT02016417
- Testing
- A combination of Gemcitabine and cisplatin, A combination of Docetaxel, cisplatin and 5-Fluorouracil
- Volunteers
- 120 people
- Sponsor
- Cancer Hospital of Guangxi Medical University
Head and Neck Cancer
Induction Chemotherapy Followed by Chemoradiation With Cetuximab in Head and Neck Cancer
The purpose of this study is to determine the efficacy and toxicity of docetaxel/cisplatin/5-fluorouracil induction chemotherapy (4 cycles) followed by concomitant chemoradiation with cetuximab and weekly cisplatin in patients…
- Trial name
- NCT00868491
- Testing
- docetaxel, cisplatin, 5-fluorouracil, radiotherapy, cetuximab, cisplatin
- Where
- Slovenia
- Volunteers
- 30 people
- Sponsor
- Institute of Oncology Ljubljana
Carcinoma of the Anal Canal
Concurrent Chemoradiation + 5-FU + Mitomycin-C in Anal Carcinoma
This research study is a Pilot Study. Pilot studies are conducted to see if it is practical to do this type of research ona larger scale in the future.
- Trial name
- NCT01858025
- Testing
- Pencil Beam scanning Radiation, 5-fluorouracil, Mitomycin-C
- Where
- 2 sites in United States
- Volunteers
- 25 people
- Sponsor
- Massachusetts General Hospital
Lung Neoplasms, Carcinoma, Non-Small-Cell Lung
Study of Pembrolizumab With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib in Stage III Non-Small Cell Lung Cancer (NSCLC) (MK-7339-012/KEYLYNK-012)
The purpose of this study is to assess the efficacy and safety of pembrolizumab in combination with concurrent chemoradiation therapy followed by either pembrolizumab with olaparib placebo (Arm 1) or with olaparib (Arm 2)…
- Trial name
- NCT04380636
- Testing
- Pembrolizumab, Olaparib, Etoposide
- Where
- 205 sites in United States, Argentina and 24 more
- Volunteers
- 870 people
- Sponsor
- Merck Sharp & Dohme LLC
Carcinoma, Small Cell, Lung Neoplasms
Hypofractionated vs. Conventionally Fractionated Concurrent CRT for LD-SCLC
The purpose of this study is to determine whether hypofractionated concurrent chemo-radiotherapy has the same efficiency as conventionally fractionated concurrent chemo-radiotherapy in Limited Disease Small Cell Lung Cancer.
- Trial name
- NCT02688036
- Testing
- hypofractionated concurrent chemoradiotherapy, conventionally fractionated concurrent chemoradiotherapy
- Where
- China
- Volunteers
- 860 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Squamous Cell Carcinoma of the Head and Neck, Carcinoma, Squamous Cell of the Head and Neck
Nab-Paclitaxel and Cisplatin or Nab-paclitaxel as Induction Therapy for Locally Advanced Squamous Cell Carcinoma of the Head and Neck (HNSCC)
In this trial, the objectives are to determine the efficacy and toxicity of induction chemotherapy (IC) with nab-paclitaxel + cisplatin (Arm 1: AP) and with nab-paclitaxel (Arm 2: A) alone in patients with HNSCC, and to compare…
- Conditions
- Squamous Cell Carcinoma of the Head and Neck, Carcinoma, Squamous Cell of the Head and Neck, Cancer of Head and Neck, Cancer of the Head and Neck
- Trial name
- APA (NCT02573493)
- Testing
- nab-Paclitaxel, Cisplatin, Cetuximab
- Where
- 3 sites in United States
- Volunteers
- 96 people
- Sponsor
- Washington University School of Medicine
Pancreatic Carcinoma
Neoadjuvant mFolfirinox With or Without Preoperative Concomitant Chemoradiotherapy in Patients With Borderline Resectable Pancreatic Carcinoma (PANDAS-PRODIGE 44)
This is a prospective, randomized phase II trial. The aim of this study is to assess the efficacy of two therapeutics strategies.
- Trial name
- NCT02676349
- Testing
- mFolfirinox, Chemoradiotherapy, surgery
- Where
- 26 sites in France
- Volunteers
- 130 people
- Sponsor
- Institut de Cancérologie de Lorraine
Glioblastoma
Temozolomide Plus Anti-angiogenesis Drugs and Radiotherapy as a Treatment for Glioblastoma
Temozolomide (TMZ) is an oral chemotherapy drug. It is an alkylating agent used as a first-line treatment for glioblastoma. This methylation damages the DNA and triggers the death of tumor cells.
- Trial name
- NCT03567135
- Testing
- Apatinib, Temozolomide（TMZ）
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Fuzhou General Hospital
Esophageal Cancer
CCRT With Twice Weekly Paclitaxel and Cisplatin Followed by Surgery for Locally Advanced Esophageal Cancer
CCRT with twice weekly paclitaxel and cisplatin in patient with locally advanced esophageal cancer.
- Trial name
- NCT00154804
- Testing
- Paclitaxel, Cisplatin,Surgery, CCRT
- Where
- Taiwan
- Volunteers
- 40 people
- Sponsor
- National Taiwan University Hospital
Cervical Cancer
A Prospective Study of Monitoring Immune Response in Locally Advanced Cervix Cancer
Perspectives: To analyse if the change of specific immune response will correlate with clinical effect of advanced cervix cancer after radio-chemotherapy.
- Trial name
- NCT03559803
- Testing
- Cisplatin
- Where
- 2 sites in China
- Volunteers
- 58 people
- Sponsor
- Sichuan University
Cervical Cancer, Locally Advanced Cervical Cancer
Neoadjuvant Chemoimmunotherapy Versus Concurrent Chemoradiotherapy for LACC
It is a prospective, open-label, randomized, controlled phase II/III clinical trial in which patients with PD-L1-positive FIGO stage IB3, IIA2 and IIB（tumors >4 cm in diameter）will be enrolled and randomly divided into the…
- Conditions
- Cervical Cancer, Locally Advanced Cervical Cancer, Concurrent Chemoradiotherapy, Neoadjuvant Chemoimmunotherapy
- Trial name
- NCT06288373
- Testing
- Camrelizumab, Cisplatin, Nab paclitaxel
- Where
- 12 sites in China
- Volunteers
- 440 people
- Sponsor
- Tongji Hospital
Head and Neck Cancer, Radiation
A Multicenter Phase II Trial of Post-operative Concurrent Chemoradiotherapy Using Weekly Cisplatin With Tislelizumab for Patients With High-risk Head and Neck Squamous Cell Carcinoma：The POTENTIAL Study
To investigate whether concurrent Tislelizumab with postoperative chemoradiotherapy would have survival benefit in high Risk HNSCC Patients.
- Conditions
- Head and Neck Cancer, Radiation, PD-1
- Trial name
- NCT04814069
- Testing
- Tislelizumab
- Volunteers
- 38 people
- Sponsor
- Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University